Vitract published new research in Nature Microbiology showing that gut bacteria can inject proteins directly into human cells using microscopic injection systems.
Public source
Publisher name
Public post
Gut bacteria do not just influence the immune system through metabolites. New research published in Nature Microbiology found that gut bacteria can inject proteins direc…
Company
Vitract
Building the future of gut microbiome health based applications
- Industry
- Biotechnology Research
- Company size
- 2–10 employees
About Vitract
Vitract is a gut microbiome testing and research company building the most advanced and affordable testing to assess gut dysbiosis.
See moreLatest activity
Latest activity from Vitract
6 signals
Presence & Recognition
Vitract is heading to Nashville to bring together a small group of local functional, integrative, longevity, and wellness providers for an evening at NEXT|HEALTH on September 11.
Presence & Recognition
Vitract is attending the NEXT|HEALTH team's inaugural Longevity Summit in Nashville.
Research & Knowledge
Vitract published a full conversation with Linta Mustafa on AI in clinical practice and functional medicine
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
DARWIN Bioprospecting Excellence
DARWIN Bioprospecting Excellence published a study by researchers from Jiangnan University in China that uncovered a natural mechanism regulating blood sugar and sugar cravings in the gut microbiome.
Research & Knowledge
MusB Research
MusB Research and Vidya Herbs published a peer-reviewed study investigating the GLP-1-promoting potential of a proprietary Akkermansia muciniphila strain in vitro.
Research & Knowledge
Probi AB
Probi AB published the latest edition of the Probi Science & Innovation Update, bringing together developments from across the company and microbiome research.
Research & Knowledge
Freya Biosciences
Freya Biosciences published a paper on the development of a bacterial chassis for engineered Live Biotherapeutic Product development, featuring an E. coli Nissle 1917 derivative using tetrathionate as terminal electron acceptor for superior engraftment in an inflamed gut.
Research & Knowledge
Earlham Institute